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Abstract
Background
Poor quality use of medicines (QUM) has adverse outcomes. Governments’ implementation
of essential medicines (EM) policies is often suboptimal and there is limited information on
which policies are most effective.
Methods
We analysed data on policy implementation from World Health Organisation (WHO) surveys
in 2007 and 2011, and QUM data from surveys during 2006–2012 in developing and transi-
tional countries. We compared QUM scores in countries that did or did not implement
specific policies and regressed QUM composite scores on the numbers of policies imple-
mented. We compared the ranking of policies in this and two previous studies, one from the
same WHO databases (2003–2007) the other from data obtained during country visits in
South-East Asia (2010–2015). The rankings of a common set of 17 policies were correlated
and we identified those that were consistently highly ranked.
Findings
Fifty-three countries had data on both QUM and policy implementation. Forty policies were
associated with effect sizes ranging from +13% to -5%. There was positive correlation
between the composite QUM indicator and the number of policies reported implemented:
(r) = 0.437 (95% CI 0.188 to 0.632). Comparison of policy rankings between the present and
previous studies showed positive correlation with the WHO 2003–7 study: Spearman’s rank
correlation coefficient 0.498 (95% CI 0.022 to 0.789). Across the three studies, five policies
were in the top five ranked positions 11 out of a possible 15 times: drugs available free at the
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point of care; a government QUM unit; undergraduate training of prescribers in standard
treatment guidelines, antibiotics not available without prescription and generic substitution
in the public sector.
Interpretation
Certain EM policies are associated with better QUM and impact increases with co-imple-
mentation. Analysis across three datasets provides a policy short-list as a minimum invest-
ment by countries trying to improve QUM and reduce antimicrobial drug misuse.
Introduction
Suboptimal (irrational, incorrect, inappropriate) use of medicines is widespread, wasteful, and
causes poor patient outcomes including anti-microbial drug resistance [1–9]. Interventions to
improve quality use of medicines (QUM) in low/middle-income countries have mostly been
small-scale, of limited duration, with small to modest effects [10–11].
Evidence from studies that we conducted in public healthcare sectors in developing and
transitional countries suggests that implementation of WHO essential medicines (EM) policies
is associated with better quality use (rational use) of medicines (QUM), including more appro-
priate use of anti-microbial agents [12–14]. The original WHO global data-set [12] covered the
period 2003–2007 and there was uncertainty about how well EM policies were executed (based
on country self-reports), with simultaneous deployment of multiple policies making it difficult
to estimate individual impacts. We accessed a second source of data collected during 2-week
visits to countries in South-East Asia during 2010–15, where policy implementation was
observed independently [14]. The analyses of these data confirmed several of the findings of
the earlier studies [12–13], including a correlation between the total numbers of EM policies
implemented and composite measures of QUM. However, it remains unclear which policies
are associated with the largest beneficial effects on medicines use.
The aims of the present work were to analyse an updated global WHO data-set (2007–
2011), which included some policies not previously evaluated, and to test the consistency of
our earlier findings of an increased impact with larger numbers of implemented EM policies.
In addition, we wished to assess replicability of findings by correlating the rankings of policies
that were common to the three studies to determine whether certain policies were consistently
associated with the largest effects.
Methods
The analytical methods used have been described previously [12–14] and are summarised
briefly here. QUM data (outcomes) were extracted from independent survey reports contained
within the WHO medicines use database for the period 2006–2012 [3] and reported policy
implementation data were obtained from WHO policy databases of surveys sent to Ministries
of Health in 2007 and 2011 [15–16]. A dataset was created with one set of QUM and policy
indicators for each country. Where the same QUM indicator was measured by more than one
survey in the same country during 2006–2012, an average value was calculated. Where the
same policy was reported differently in 2007 and 2011, the policy information reported from
within one year of QUM survey was used or if this was not possible the data were excluded.
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Indicators
Thirteen QUM indicators were extracted from the WHO medicines use database [3]. Only
surveys using recommended validated measures estimated from at least 600 prescriptions and/
or three or more facilities were included [17–18]. The QUM indicators were all expressed as
proportions and are described in Table 1, together with the directionality of better (or worse)
QUM. Ten indicators were used in the previous analysis of WHO data [12].
Fifty-two indicators of reported policy implementation were extracted (49 from WHO
questionnaires sent to Ministries of Health in 2007 and 2011 [19] and 3 from the WHO medi-
cines use database [3]). The selected EM policies included all those that had been associated
with better QUM in the previous two studies [12–14]; all were categorised as yes/no variables.
Policies were excluded from analysis if there were fewer than six countries reporting imple-
mentation or non-implementation of the policy as was done previously [12].
Where policy indicators overlapped, only one was included. Where there was more than
one indicator with a time-frame we included the one with the largest sample size. Through this
process the number of policy indicators was reduced to 40 (reasons given in Table 2).
Eight policy indicators had not been analyzed in previous studies: availability of essential
medicine list (EML) booklets at health facilities; existence of national legislation on drug pro-
motion; prohibition of advertising prescription-only medicines to the public, a national task
force to contain antimicrobial resistance and four policies concerning pharmacists—under-
graduate training on the EML and standard treatment guidelines (STGs), continuing profes-
sional development and whether pharmacists prescribed in primary care (Table 2).
Analyses
As previously [12–14], we did not try to perform head-to-head comparisons of different poli-
cies. Countries implemented different combinations of policies, so the impact of a single policy
could not be separated from those that were co-implemented.
Table 1. Indicators of Quality use of Medicines (QUM) and direction of better use.
Variable Name Direction of better use
1 % patients prescribed antibiotics Less
2 % patients not needing antibiotics that are prescribed them Less
3 % upper respiratory tract infection cases treated with antibiotics Less
4 % pneumonia cases treated with an appropriate antibiotic More
5 % diarrhoea cases treated with antibiotics Less
6 % diarrhoea cases treated with oral rehydration solution More
7 % diarrhoea cases treated with anti-diarrhoeal drugs Less
8 % malaria cases treated with an appropriate anti-malarial�� More
9 % prescribed drugs belonging to the Essential Medicines List More
10 % drugs prescribed by generic name More
11 % patients prescribed vitamins (mainly B complex & multivitamin) Less
12 % patients prescribed injections Less
13 % patients treated in compliance with standard treatment guidelines More
� Thirteen standard medicines use indicators [17–18] expressed as proportions and reported in surveys in more than
8 countries during 2006–2012.
�� One indicator (% patients treated with an appropriate anti-malarial) was not used in any of the previous studies
[12–14]. However, assuming that overall measurement of QUM will be more robust with more individual QUM
indicators, and due to the large number of studies measuring antimalarial use in recent years, it was decided to
include this extra QUM indicator on antimalarial use in this study.
https://doi.org/10.1371/journal.pone.0228201.t001
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Table 2. Medicines policies hypothesised to improve quality use of medicines (QUM).
Educational policies Inclusion/exclusion from analysis with reasons Whether policy was measured
in one or both of previous two
studies�
1 Public education on medicines use in the last two years Included Yes
2 Undergraduate training of doctors on the national
Standard Treatment Guidelines (STGs)
Included Yes
3 Undergraduate training of pharmacists on the national
STGs
Included No
4 Undergraduate training of doctors on the national
Essential Medicines List (EML)
Included Yes
5 Undergraduate training of pharmacists on the national
EML
Included No
6 Mandated continuing medical education that includes
quality use of medicines (QUM) for doctors
Included Yes
7 Mandated continuing medical education that includes
QUM for pharmacists
Included No
8 Mandated continuing medical education that includes
QUM for nurses and/or paramedical staff
Included Yes
Managerial policies
9 Availability of Essential Medicines List booklet at health
public�� (from patient care indicators)
Included No
10 Availability of Standard Treatment Guidelines booklet at
health public�� (from patient care indicators)
Included Yes
11 Better drug supply�� (as indicated by better drug
availability from patient care indicators)
Included Yes
12 National Essential Medicines List (EML) updated in the
last five years
Excluded, as insufficient numbers of country responded “no” to
make a comparison
13 National Essential Medicines List (EML) updated in the
last two years
Included Yes
14 National Formulary updated in the last five years Included Yes
15 National Formulary updated in the last two years Excluded, as duplicative of the policy on formulary updated in last 5
years
16 National Standard Treatment Guidelines (STGs)
updated in the last five years
Excluded as duplicative of the policy on national STGs updated in
the last 2 years and more even distribution of countries with &
without the policy
17 National Standard Treatment Guidelines updated in the
last two years
Included Yes
18 Prescription audit done any time in the past Excluded, as prescription audit in the last two years was felt to be
more indicative of active policy
19 Prescription audit in the last two years Included Yes
20 Generic prescribing policy in public sector Included Yes
21 Generic substitution in public sector Included Yes
Regulatory policies
22 Active monitoring of Adverse Drug Reactions (ADRs) Included Yes
23 Antibiotics generally NOT available over-the-counter
(OTC) (never/occasional = No; always/frequently = Yes)
Included Yes
24 Injections generally NOT available over-the-counter
(never/occasional = No; always/frequently = Yes)
Included Yes
25 National legislation on drug promotion Included No
26 Co-regulation of drug promotion by government and
industry
Included Yes
27 Pre-approval of adverts for over-the-counter (OTC)
medicines undertaken
Included Yes
28 Existence of guidelines for the advertising of OTC
medicines
Excluded as very few countries had such guidelines and this policy is
partially duplicative of the policy on pre-approval of OTC drug
adverts
(Continued)
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Table 2. (Continued)
Educational policies Inclusion/exclusion from analysis with reasons Whether policy was measured
in one or both of previous two
studies�
29 Prohibition of advertising of prescription-only
medicines to the public
Included No
Structural policies
30 Existence of a National Medicines Policy document Excluded, as insufficient numbers of country responded “no” to
make a comparison
31 National medicines policy implementation plan Included Yes
32 National Ministry of Health (MOH) unit on promoting
rational use of medicines
Included Yes
33 Presence of National Drug Information Centre Included Yes
34 National strategy to contain antimicrobial resistance
(AMR)
Included Yes
35 National task force to contain AMR Included No
36 National reference laboratory for AMR Excluded, as duplicative of other policies on antimicrobial resistance
containment
37 Drug and Therapeutic Committee (DTC) in half or
more of all referral hospitals
Included Yes
38 Drug and Therapeutic Committee in half or more of all
general hospitals
Included Yes
39 Drug and Therapeutic Committee in half or more of all
provinces
Excluded, as duplicative of DTCs in general hospitals
40 Ministry of Health regulation to have Drug and
Therapeutic Committees
Excluded, as duplicative of other DTC policies
Economic policies
41 All drugs on the national Essential Medicines List (EML)
provided free of charge in a national health or social
insurance system
Included Yes
42 Drugs dispensed free of charge to pregnant women Excluded as partially duplicative of drugs dispensed free of charge to
children and not measured in previous studies
43 Drugs dispensed free of charge to the poor Included Yes
44 Drugs dispensed free of charge to children under five
years
Included Yes
45 Drugs dispensed free of charge to the elderly Excluded as duplicative of other free drug policies
46 NO Drug sales revenue used to supplement prescriber
income
Included Yes
47 NO user fees for medicines Included Yes
48 NO fees for consultation or registration Included Yes
49 Prescribers dispense in the public sector Excluded as the number of countries with this policy was small and
the policy indicator does not address the important issue of
prescribers who earn money from drug sales generally in the private
sector. In addition, it was not measured in previous studies.
Human resource management policies
50 Prescribing by pharmacists in public primary care Included No
51 No prescribing by staff with less than one month’s
training in public primary care
Included Yes
52 Prescribing by nurses and/or paramedical staff in public
primary care
Included Yes
� Includes all policies found to be associated with improved QUM as found in previous studies [12–14].
�� Patient care indicators extracted from the Medicines Use Database and where the countries with values above the median across countries are classified as having
better implementation of national STGs/EML and drug supply respectively.
https://doi.org/10.1371/journal.pone.0228201.t002
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For each QUM indicator we calculated the mean difference (expressed as a percentage)
between countries reporting implementation (or not) of specific policies. For each policy, we
estimated the average difference across all 13 QUM indicators, aligning directionality of better
use (positive number) and worse use (minus number), and including only those QUM indica-
tors where there were at least three countries with and three without the policy in question
[12].
To assess the impact of multiple policies we generated a composite QUM score from 13
QUM indicators, which enabled all countries to be included in the analysis [12]. We calculated
how far each country’s value lay above or below the mean value from all countries for each
QUM indicator expressed as standard deviation (SD) units. We then calculated the average of
the SD unit increments across the thirteen QUM indicators for each country and used linear
regression to assess correlation with the number of EM policies that were implemented [12].
We limited these analyses to policies that had a statistically significant association with better
QUM in the univariate analyses.
Individual QUM indicators were also regressed on the number of implemented policies to
determine whether specific aspects of QUM were influenced by the intensity of policy imple-
mentation. The impact of country wealth was assessed by including Gross National Income
per capita [20] in multiple linear regression analyses and by repeating the regression analyses
for countries with GNIpc above and below the median of USD 2315.
Testing the replicability of findings across three studies
Statistical analysis methods used in the present study were the same as those used in the earlier
WHO analysis [12–13] and the SE Asia country visit analysis [14], enabling us to compare
findings across three studies [12–14]. For each of the three data-sets we ranked the policies
based on their estimated impact from the univariate analyses. We used non-parametric regres-
sion analysis to measure the correlation between the ranking of the policies that were common
to the three studies [12–14]. We established the overall ordering of policies by calculating the
sum of their ranks across the 3 studies. All analyses were done in Excel 2016, using either Epi
Info (version 7.2.1.0)- or Stats Direct (version 3.1.20).
All work involved secondary analyses of data collected for other purposes. Data were aggre-
gated at the level of countries or policies, not individuals, so research ethics board approval
was not required.
Results
Fifty-three countries had data on both QUM and policy implementation. Regional distribution
of countries was Africa (23), Eastern Mediterranean (7), Europe (2), Latin America (2), South-
East Asia (11) and Western Pacific (8). On average, data were available from a median of 2
(range 1–30) QUM surveys and 4 QUM indicators (range 1–13) per country. Each QUM indi-
cator was used by a median of 19 countries (range 9–37). Out of a potential 2120 policy
responses (40 policies in each of 53 countries), 1787 (84%) were available for analysis. Of four-
teen countries reporting policies in both 2007 and 2011, 85 (18%) responses out of a potential
476 policy responses (34 policies [measured in both 2007 and 2011] x 14 countries) were
reported differently and of these 54 (11%) were excluded. Supporting information (S1 Table)
describes the 13 QUM indicators and 3 policy indicators obtained from the WHO medicines
use database, by country together with the survey references. Supporting information (S2
Table) describes information on the reported implementation of 52 policies by country. Sup-
porting information (S3 Table) describes the impact of common policies in this study and the
two previously published studies–this being the data used in the replicability analysis.
Essential medicine policies and quality use of medicines
PLOS ONE | https://doi.org/10.1371/journal.pone.0228201 February 6, 2020 6 / 16
Strength of associations for individual policies
Table 3 shows the estimates of policy effect on QUM by policy type, comparing results in
countries that did, or did not, report implementation. Fig 1 shows these results in order of
their estimated effect size.
Policies that were statistically significantly associated with 5–10% or higher effects on QUM
included: drugs free at the point of care for children less than five years and the poor; generic
substitution; a national strategy to contain antimicrobial resistance; a national body dedicated
to QUM; booklets of the national essential medicines lists and standard treatment guidelines
available at health facilities; not having systemic antibiotics available over-the-counter; an
updated national formulary; no prescriber revenue from medicine sales; national legislation
on drug promotion; public education; all drugs on the national Essential Medicines List
(EML) provided free of charge in a national health or social insurance system; drug and thera-
peutic committees in hospitals; and undergraduate education of doctors and pharmacists on
standard treatment guidelines.
Of the 27 policies that were associated with positive effects, the average estimated effects
were: 9.3% (range 7.0 to 13.0)% for economic policies; 7.4% (2.3 to 10.5%) for managerial poli-
cies; 7.3% (range 5.6 to 10.2%) for structural policies; 4.9% (range 2.3 to 6.8%) for educational
policies; 4.9% (range 1.7 to 8.6%) for regulatory policies, and 4.2% (range 3.2 to 5.1%) for
human resource management policies.
Impacts of multiple policies and national wealth
Fig 2 shows a scatter-gram of composite QUM scores versus the number of policies reported
implemented. Correlation between the composite QUM indicator and the number of signifi-
cantly effective policies reported as implemented (out of 18) was moderate (r = 0.437; 95% CI
0.188 to 0.6322) and strengthened when regression was limited to countries with more than
two QUM indicators (r = 0.510; 95% CI 0.243 to 0.704). Inclusion of a national wealth measure
(GNIpc) in the regression had no effect (r = 0.51; 95% CI 0.243 to 0.704) and the correlation
coefficients were similar when analyses were conducted separately for countries with GNIpc
levels above (r = 0.55, p = 0.018) and below the group median (r = 0.41, p = 0.048)).
When we examined the impact of multiple policies on individual QUM indicators (Sup-
porting information S4 Table) we found that the percentage of all cases treated with antibiotics
was significantly less with implementation of a greater number of policies (r = -0.375; 95% CI
-0.624 to -0.059) as was the percentage of upper respiratory tract infection cases treated with
antibiotics (r) = -0.554; 95% CI -0.796 to -0.161. Fig 3 shows a scatter-gram of the percentages
of upper respiratory tract infection cases treated with antibiotics versus the number of policies
reported implemented. The differences in the percentage of upper respiratory tract infection
cases treated with antibiotics were large, ranging from 80–100% in countries implementing
less than four EM policies to 30–70% in countries implementing more than 15 policies.
Replicability of effects across studies
Table 4 summarises the results for 17 policies that were common to the three studies ordered
by the sum of the ranks across the three studies. The table also provides the individual study
rankings and whether the univariate analyses of effect sizes had 95% CI that excluded zero. We
found a significant correlation between the ranking (24 common policies) in the present study
(2007–2011) and that found in the previous analysis of WHO global data (2003–2007): rank
correlation coefficient Rho = 0.498 (95% CI 0.022 to 0.789). Correlation between the ranking
(20 common policies) in the current analysis and that from the SE Asia country visits was
weaker: Rho = 0.465 (95% CI -0.020 to 0.773). Nine policies had effect sizes of 4–10% that were
Essential medicine policies and quality use of medicines
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Table 3. Difference in medicines use across 13 QUM indicators between countries reporting implementation / non-implementation of 40 essential medicines
policies.
Average difference across all QUM indicators where number of
countries per QUM indicator per arm of policy implementation
is >2 countries
No. QUM indicators in
av. diff. calculation
Average (Av.) difference
(diff.) in QUM with 95% CI
Whether policy included in variable on
number of EM policies implemented�
EDUCATIONAL POLICIES
1 Public education on medicines use in the last two years 13 6.8 (4 to 10) Yes
2 Undergraduate training of pharmacists on the national
Standard Treatment Guidelines (STGs)
12 6.3 (2 to 11) Yes
3 Undergraduate training of doctors on the national STGs 12 5.4 (2 to 9) Yes
4 Undergraduate training of doctors on the national Essential
Medicines List (EML)
12 3.8 (-1 to 9) No
5 Undergraduate training of pharmacists on the national EML 12 2.3 (-3 to 7) No
6 Continuing medical education of pharmacists 13 -0.8 (-7 to 5) No
7 Continuing medical education of doctors 13 -2.4 (-8 to 3) No
8 Continuing medical education of nurses and/or paramedical
staff
13 -5.1 (-14 to 4) No
MANAGERIAL POLICIES
9 Generic substitution in public sector 11 10.5 (3 to 18) Yes
10 Availability of Essential Medicines List booklet at health
public�� (from patient care indicators)
9 10.3 (4 to 16) Yes
11 Availability of Standard Treatment Guidelines booklet at
health public�� (from patient care indicators)
10 9.8 (1 to 19) Yes
12 National Formulary updated in the last five years 11 8.2 (3 to 14) Yes
13 Prescription audit in the last two years 5 5.5 (-5 to 16) No
14 Better drug supply�� (as indicated by better drug availability
from patient care indicators)
13 5.0 (-3 to 13) No
15 Generic prescribing policy in public sector 13 2.3 (-5 to 10) No
16 National Essential Medicines List (EML) updated in the last
two years
11 0.9 (-3 to 5) No
17 National Standard Treatment Guidelines (STGs) updated in
the last two years
13 -3.3 (-8 to 2) No
REGULATORY POLICIES
18 Antibiotics generally NOT available over-the-counter (OTC)
(never/occasional = No; always/frequently = Yes)
5 8.6 (2 to 16) Yes
19 National legislation on drug promotion 12 6.8 (1 to 12) Yes
20 Injections generally NOT available over-the-counter (OTC)
(never/occasional = No; always/frequently = Yes)
9 0.0 (-9 to 9) No
21 Prohibition of advertising of prescription-only medicines to
the public
4 2.5 (-13 to 18) No
22 Active monitoring of Adverse Drug Reactions (ADRs) 13 1.7 (-4 to 8) No
23 Co-regulation of drug promotion by government and
industry
7 -0.5 (-7 to 6) No
24 Pre-approval of adverts for over-the-counter (OTC)
medicines undertaken
7 -2.4 (-9 to 5) No
STRUCTURAL POLICIES
25 National task force to contain AMR 6 11.1 (0 to 23) Yes
26 National strategy to contain antimicrobial resistance (AMR) 11 10.2 (5 to 16) Yes
27 National Ministry of Health (MOH) unit on promoting
Quality Use of Medicines (QUM)
10 9.8 (3 to 17) Yes
28 Drug and Therapeutic Committee in half or more of all
general hospitals
11 7.3 (0 to 15) Yes
29 Drug and Therapeutic Committee (DTC) in half or more of
all referral hospitals
13 5.6 (1 to 11) Yes
(Continued)
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statistically significant in two or more of the three studies. Five policies had consistently high
positions in the orderings (highlighted in Table 4), appearing in the top 5 ranked positions 11
out of a possible 15 times. They were: medicines free at the point of care; the presence of a gov-
ernment QUM unit, undergraduate training of prescribers in STGs, antibiotics not available
without prescription and generic substitution allowed in the public sector. Statistically signifi-
cant better QUM associated with implementation of more policies was seen in all three studies
[12–14].
Discussion
The main findings from the current study of the most recent WHO data-bases were three-fold.
Firstly, some essential medicines policies were associated with better QUM. The strongest
associations were for: medicines free at the point of care, implementation of STGs and the
EML, a national body to promote QUM, a national strategy to contain AMR, disallowing anti-
biotic availability OTC, generic substitution in the public sector, hospital DTCs, and public
education. Secondly, all policy categories had similar overall degrees of association with better
QUM. Thirdly, there was a positive correlation between the number of policies that countries
reported implementing and their measures of QUM.
The WHO data have significant limitations, notably the reliance on self-report and the vari-
able co-implementation of several policies, making it difficult to discern the true effects of indi-
vidual policies. In addition, multiple policies and QUM measures make chance associations
likely and limit the interpretation of statistical significance testing. In this situation a consistent
finding of a relationship between intensity of policy implementation (number of policies) and
a composite measure of QUM is important. In this and previous studies [12–14], there were
Table 3. (Continued)
Average difference across all QUM indicators where number of
countries per QUM indicator per arm of policy implementation
is >2 countries
No. QUM indicators in
av. diff. calculation
Average (Av.) difference
(diff.) in QUM with 95% CI
Whether policy included in variable on
number of EM policies implemented�
EDUCATIONAL POLICIES
30 Presence of National Drug Information Centre 12 0.6 (-8 to 9) No
31 National medicines policy implementation plan 12 -3.5 (-15 to 8) No
ECONOMIC POLICIES
32 Drugs dispensed free of charge to the poor 12 13.0 (6 to 20) Yes
33 Drugs dispensed free of charge to children under five years 12 12.2 (5 to 19) Yes
34 NO Drug sales revenue used to supplement prescriber income 13 7.9 (2 to 14) Yes
35 All drugs on the national Essential Medicines List (EML)
provided free of charge in a national health or social
insurance system
12 6.3 (3 to 9) Yes
36 NO user fees for medicines 12 7.0 (-2 to 15) No
37 NO fees for consultation or registration 7 0.0 (-6 to 6) No
HUMAN RESOURCE MANAGEMENT POLICIES
38 Prescribing by pharmacists in public primary care 13 5.1 (-3 to 14) No
39 No prescribing by staff with less than one month’s training in
public primary care
11 3.2 (-4 to 11) No
40 Prescribing by nurses and/or paramedical staff in public
primary care
8 -5.1 (-11 to 1) No
� The variable on the number of policies reported implemented was adjusted for missing data as follows: adjusted policy number = (number of policies reported/(N-
number of missing values for policies)) x N, where N was the number of effective policies [12].
https://doi.org/10.1371/journal.pone.0228201.t003
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moderate associations between implementation of more EM policies and better QUM, as
reflected by both a composite QUM indicator and individual QUM indicators, notably lower
antibiotic use in upper respiratory tract infection. The strength of association seen in this
study was like those seen in the previous analyses of WHO global data [12] and data from SE
Asia [14]. Unlike the previous two studies the association between EM policies and QUM
appeared to be weaker in poorer countries than in wealthier ones, although the association was
stronger when regression analysis was limited to more robust QUM data (based on more than
2 QUM indicators).
Although analyses of multiple policy exposure are valuable, these analyses have their own
limitations. Most importantly, the exposure variable is the number of equally weighted policies
and this does not assist in the identification of the most effective policies. With potentially
large numbers of policies and co-variates, and modest number of countries, it was not possible
to perform multi-variable analyses and conduct comparisons of individual policies. For these
reasons, we assessed the replicability of the ordering of policies by estimated effects across the
three studies we have completed. The correlations of the rank orders between the present and
previous analyses were modest when measured across the full set of 17 policies that were com-
mon to each study. However, the five highest ranking policies (Table 4) occupied the top five
places on 11 out of a possible 15 occasions.
In a situation defined by weak data we think the replicability we found across three separate
studies, using almost identical methods, is the strongest evidence for identifying the most
effective essential medicines policies. We are not suggesting that these policies are the only
ones that should be considered for implementation. Countries with particular needs may
Fig 1. Differences in quality use of medicines between countries that did versus did not report implementation of specific medicine policies. Bars and numbers
represent the estimated mean effect and 95% CI for the mean effect of each policy on a composite measure of QUM. X-axis acronyms: AMR = antimicrobial resistance;
EML = Essential Medicines List; QUM = Quality Use of Medicines; STG = Standard Treatment Guideline; OTC = Over-the-Counter; DTC = Drug and Therapeutic
Committee; ADR = Adverse Drug Reaction; CME = Continuing Medical Education.
https://doi.org/10.1371/journal.pone.0228201.g001
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choose from a larger basket of policies. However, five apparently strong policies, each from a
different category, represents a minimum investment for countries seeking to improve QUM
and optimize the consumption of antimicrobial drugs. The policies are: drugs free at the point
of care; existence of a government QUM unit; undergraduate prescriber training in standard
treatment guidelines; antibiotics not available over the counter without prescription and
generic substitution allowed in the public sector. Because they come from different policy cate-
gories it is possible that they have complementary effects, although that couldn’t be tested
here.
Comparison with the broader literature
Previous reviews have recommended implementing similar policies to improve QUM [21–
22]. Other studies reporting on actual policy effectiveness reported on: prescriber education
[10–11]; public education [23–24]; an MOH body dedicated to promoting QUM [25]; hospital
drug and therapeutic committees (DTCs) [26]; non-allowance of prescriber revenue from
medicine sales [27–29]; non-allowance of antibiotic availability OTC [30], and national legisla-
tion and monitoring of drug promotional activities [31]. Greater effectiveness of multi-faceted
interventions (which may involve multiple localised policies), as opposed to single-faceted
ones, has also been found elsewhere [32–34]. Furthermore, the better QUM seen here with
implementation of more policies was large and comparable with intervention effects reported
elsewhere [10–11, 32–34]. However, the sustainability of the better QUM achieved with
national medicines policy implementation is likely to be much greater than that achieved with
the discrete interventions implemented locally.
Fig 2. Scatter-gram of the composite QUM indicator score versus the number of policies reported implemented. Data is good enough to show better QUM with
implementation of more policies, but not to benchmark country performance.
https://doi.org/10.1371/journal.pone.0228201.g002
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Limitations
We have extensively discussed the limitations of the WHO data-bases above and in previous
reports [12–13]. The policy data used are reliant on self-reports of implementation, which may
have been inaccurate, and the apparent effectiveness of individual policies may have been due
to co-interventions. The small number of countries, large numbers of possible policy combina-
tions, and other factors, including political will and economic stability, can reduce implemen-
tation effectiveness and hamper attempts to estimate the impacts of individual policies or
specific policy combinations. Another weakness of the data was the assumption that policies
may have remained the same over time. However, the fact that there were only small differ-
ences between estimates from countries reporting policy implementation for both 2007 and
2011 suggests that most policies generally remained constant. Furthermore, misreporting and
misclassification would likely have weakened any associations seen between policy implemen-
tation and QUM.
There were weaknesses in the QUM data. Firstly, they come from surveys published in the
literature. While only surveys using standard methodology and indicators [17–18] were used,
they were often based on small sample sizes. Secondly, although standard QUM indicators
were used, some were probably measured differently across studies. Thirdly, for some coun-
tries there were only one or two QUM indicators measured. This gave a less robust picture of
overall QUM and was the reason for use of a composite QUM indicator that allowed all coun-
tries to be included in the regression analyses. A few countries had outlier QUM estimates
based on only 1–2 indicators; this was a possible explanation for the stronger correlation
between number of policies implemented and better QUM when the analysis was confined to
Fig 3. Scatter-gram of the % upper respiratory tract infection cases treated with antibiotics versus the number of policies reported implemented. Data is good
enough to show less antibiotic use in upper respiratory tract infection with implementation of more policies, but not to benchmark country performance.
https://doi.org/10.1371/journal.pone.0228201.g003
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countries reporting three or more QUM indicators. Finally, the clinical relevance of a compos-
ite QUM indicator is not clear, but the component indicators have relevance and we aligned
each to ensure that directionality of change was constant. As with uncertainty over policy vari-
ables, any inaccuracies of medicine use estimates would likely have weakened any associations
seen between policy implementation and QUM.
Table 4. Summary of ranking of policies and statistical conclusions from univariate analyses across three studies.
Policy Policy type Present study (Global data
2007–2011)
SE Asia data 2010–15 [14] Global data 2003–2007 [12] Overall
Study effect
estimate�
Study
rank
Stat
sig��
Study effect
estimate�
Study
rank
Stat
sig��
Study effect
estimate�
Study
rank
Stat
sig��
Sum of
ranks$
Overall
rank
Drugs free at the point of
care
Economic 10.7 1 Yes 9.5 1 Yes 9.3 3 Yes 5 1
Government Quality Use of
Medicines unit
Structural 9.8 4 Yes 9.0 4 Yes 10.9 1 Yes 9 2
Undergraduate Prescriber
Standard Treatment
Guideline training
Educational 5.9 10 Yes 9.2 2 Yes 10.1 2 Yes 14 3 =
Antibiotics not available
Over-The-Counter
Regulatory 8.6 5 Yes 9.2 2 Yes 7.0 7 Yes 14 3 =
Generic substitution in the
public sector
Managerial 10.5 2 Yes 4.4 10 No 6.6 9 Yes 21 5
Drug & Therapeutic
Committees in more than
half of health facilities
Structural 6.4 9 Yes 5.1 9 No 7.5 5 Yes 23 6
National Antimicrobial
Resistance Strategy
Structural 10.2 3 Yes 1.5 16 No 7.2 6 No 25 7
No prescriber revenue from
drug sales
Economic 7.9 7 Yes 7.8 6 Yes 3.8 13 No 26 8
National Formulary manual
updated in last 5 years
Managerial 8.2 6 Yes 3.6 11 Yes 6.1 10 Yes 27 9 =
Public education on
medicines use in last 2 years
Educational 6.8 8 Yes 5.5 8 Yes 5.3 11 Yes 27 9 =
Generic prescribing policy in
the public sector
Managerial 2.3 14 No 8.0 5 No 4.3 12 No 31 11
Prescription audit in last 2
years
Managerial 5.5 11 No 7.4 7 No 3.3 15 No 33 12
Undergraduate Prescriber
Essential Medicine List
training
Educational 3.0 13 No 3.0 13 No 6.4 8 Yes 34 13
National Drug Information
Centre
Structural 0.6 16 No -2.8 17 No 8.2 4 Yes 37 14
No unqualified prescribers Human
resources
3.2 12 No 2.3 14 No 3.5 14 No 40 15
National Essential Medicine
List updated in the last 2
years
Managerial 0.9 15 No 3.2 12 No 1.9 16 No 43 16
National Standard Treatment
Guidelines updated in the
last 2 years
Managerial -3.27 17 No 1.6 15 No -0.2 17 No 49 17
� Quantitative impact based on univariate analysis in each of the individual three studies.
�� 95% CI for effect estimate that did not include zero.
$ Sum of individual study ranks for each policy
https://doi.org/10.1371/journal.pone.0228201.t004
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Our results were limited to the public sector, since there were insufficient QUM data from
the private sector. While the private sector may provide most health care in many low and
middle-income countries, the findings are still important since many prescribers work in both
sectors and many policies are aimed at both the private and public sectors.
Conclusions
In conclusion, repeated analyses of independent data-sets have shown replicability of two prin-
cipal findings. The first is that five apparently robust essential medicines policies appear to rep-
resent the best choices for countries trying to improve medicines use, and the second one is
that the implementation of multiple policies increases their effects. In 2016 The Lancet Com-
mission on Essential Medicines identified five crucial areas of essential medicines policy.
Three of these: paying for a basket of essential medicines, making essential medicines afford-
able and promoting quality use of medicines are strongly supported by the findings of this
study [1].
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